Prestige Consumer Healthcare (PBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Prestige Consumer Healthcare (PBH) reported $274.11 million in revenue for the quarter ended September 2025, representing a year-over-year decline of 3.4%. EPS of $1.07 for the same period compares to $1.09 a year ago.

The reported revenue represents a surprise of +6.87% over the Zacks Consensus Estimate of $256.49 million. With the consensus EPS estimate being $0.97, the EPS surprise was +10.31%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Prestige Consumer Healthcare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- OTC Healthcare- International: $43.36 million versus the three-analyst average estimate of $42.11 million. The reported number represents a year-over-year change of -1.4%.
• Revenues- OTC Healthcare- North American: $230.76 million versus the three-analyst average estimate of $214.98 million. The reported number represents a year-over-year change of -3.8%.
• Gross profit- OTC Healthcare- North American: $128.41 million compared to the $123.59 million average estimate based on two analysts.
• Gross profit- OTC Healthcare- International: $23.17 million versus the two-analyst average estimate of $22.22 million.

View all Key Company Metrics for Prestige Consumer Healthcare here>>>

Shares of Prestige Consumer Healthcare have returned -5.5% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Prestige Consumer Healthcare Inc. (PBH): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research